Non-Invasive Prenatal Testing Market | 2021-28 | Share Report
Non-Invasive Prenatal Testing (NIPT) Market Share, Size, Trends, Industry Analysis Report, 2021 - 2028

Non-Invasive Prenatal Testing (NIPT) Market Share, Size, Trends, Industry Analysis Report, By Gestation Period (0-12 weeks, 13-24 weeks, 25-36 weeks); By Component (Consumables, Instruments, Software, Services); By Method; By Application; By End-Use; By Regions; Segment Forecast, 2021 - 2028

  • Published Date:Apr-2021
  • Pages: 120
  • Format: PDF
  • Report ID: PM1836
  • Base Year: 2020
  • Historical Data: 2016 - 2019

Report Summary

The global Non-Invasive Prenatal Testing (NIPT) market size was valued at USD 2.89 billion in 2020 and is expected to grow at a CAGR of 11.0% during the forecast period. NIPT is increasingly being adopted for the detection of chromosomal abnormalities through DNA analysis before the birth of a baby. Non-Invasive Prenatal Testing (NIPT) is usually performed after 10 weeks of pregnancy for the detection of genetic disorders such as Down syndrome in early pregnancy.

Non-Invasive Prenatal Testing (NIPT) offers higher accuracy and detection rate than other screening tests. The Non-Invasive Prenatal Testing (NIPT) market is experiencing growth owing to rising cases of genetic disorders, changing consumer lifestyles, and growing demand from developing countries. Governments across the globe are introducing strict healthcare regulations, encouraging market players to develop effective, affordable, and patient-friendly non-invasive prenatal testing.

Prenatal cell-free DNA screening analyzes fetal DNA in the maternal bloodstream for detection of risk through chromosomal abnormalities. It is also used for revealing other chromosome problems and information associated with fetal sex. Non-Invasive Prenatal Testing (NIPT) offers high reliability, safety, and accuracy for the detection of the three common trisomies including chromosomes 21, 18, and 13.

Increasing awareness regarding fetal testing and changing consumer lifestyles has increased the demand for these tests. New product launches and acquisitions by leading players in the market coupled with technological advancements further boost the market growth across the globe.

Know more about this report: Request for sample pages

Industry Dynamics

Growth Drivers
In June 2019, Illumina, Inc., a major player in the global non-invasive prenatal testing, introduced VeriSeq Non-Invasive Prenatal Testing (NIPT) Solution v2. This solution uses a next-generation sequencing approach for screening a wide range of chromosomal and sub-chromosomal conditions. It offers detection of abnormalities associated with birth defects and adverse pregnancy outcomes. The solution assists in the delivery of informed, timely, and personalized pregnancy management options.

The solution is also capable of screening for aneuploidy, partial deletions, and duplications across the genome. It offers high sensitivity and high specificity along with fast turnaround times. The new product launch enhances the company’s offerings in the market while strengthening its presence in Europe, and the Middle East & Africa.

The Non-Invasive Prenatal Testing (NIPT) market is expected to be driven by factors such as technological advancements, rising awareness regarding early fetal testing, and advancing maternal age. The increasing occurrence of chromosomal disorders and medical insurance are fueling the market growth. The introduction of advanced technologies by leading market players, favorable reimbursement policies, and rising demand for non-invasive testing boost the adoption of non-invasive prenatal testing.

The global market is also influenced by the growing demand in countries such as China, Japan, and India, rising healthcare expenditure, and the high accuracy offered by these tests. Global players are expanding into developing countries to tap market potential, further boosting the market growth.

Non-Invasive Prenatal Testing (NIPT) Market
Know more about this report: Request for sample pages

Non-Invasive Prenatal Testing (NIPT) Market Report Scope

The market is primarily segmented on the basis of the gestation period, component, method, application end-use, and region.

By Gestation Period

By Component

By Method

By Application

By End-Use

By Region

  • 0-12 weeks
  • 13-24 weeks
  • 25-36 weeks
  • Consumables
  • Instruments
  • Software
  • Services
  • Cell-Free DNA in Maternal Plasma Tests
  • Ultrasound Detection
  • Biochemical Screening Tests
  • Others
  • Monosomy
  • Trisomy
  • Microdeletion Syndrome
  • Others
  • Diagnostic Centers
  • Hospitals
  • Clinics
  • Others
  • North America (U.S., Canada)
  • Europe (Germany, UK, France, Italy, Spain, RoE)
  • Asia Pacific (China, India, Japan, South Korea, RoAPAC)
  • Latin America (Brazil, Mexico, Columbia, RoLATAM)
  • Middle East & Africa (Saudi Arabia, South Africa, Israel, UAE, RoMEA)

Know more about this report: request for sample pages

Gestation Period Outlook

The gestation period segment has been divided into 0 - 12 weeks, 13 - 24 weeks, 25 - 36 weeks. First-trimester testing is done around the 10th week and provides an early diagnosis. Testing done during the 0 - 12th week offers early analysis, timely medical treatment, and management during and after delivery. Non-Invasive Prenatal Testing (NIPT) during the first trimester includes ultrasound among others to offer highly accurate results associated with chromosomal abnormalities such as down’s syndrome, heart abnormalities, and cystic fibrosis, among others.

Component Outlook

The component segment has been divided into consumables, instruments, software, and services. The consumables segment accounted for a major share of the global non-invasive prenatal testing industry owing to the growing demand for disposables, kits, and reagents. The growing need for advanced fetal diagnosis, supportive government regulations, and technological advancements supplement the growth of this segment.

Application Outlook

The application segment has been divided into monosomy, trisomy, microdeletion syndrome, and others. The trisomy accounted for a major share of the global non-invasive prenatal testing industry. There have been increasing cases of trisomy detected with rising maternal age, thereby increasing the adoption of NIPT. Higher accuracy offered by NIPT at the early stages of pregnancy supports the growth of this segment. Growing awareness regarding NIPT in developing countries, rising healthcare expenditure, and technological advancements boost the growth of this segment.

Method Outlook

On the basis of method, the market is segmented into cell-free DNA in maternal plasma tests, ultrasound detection, biochemical screening tests, and others. The demand for cell-free DNA in maternal plasma is expected to increase during the forecast period. The method includes analysis of cell-free fetal DNA from the plasma of pregnant women. This method offers high accuracy in the detection of trisomy, preventing complications in the second or third trimester.

End-Use Outlook

On the basis of end-user, the market is segmented into diagnostic centers, hospitals, clinics, and others. The diagnostic centers segment dominated the global non-invasive prenatal testing market in 2020. The presence of specialized equipment, advanced healthcare infrastructure, supportive government regulations, and the presence of experienced medical professionals in diagnostic centers boost the growth of this segment.

Geographic Overview

North America dominated the global non-invasive prenatal testing market in 2020. The increasing occurrence of chromosome abnormalities, growing research and development activities, and technological advancements are some factors attributing to the growth of this region. The established healthcare infrastructure, rising awareness regarding fetal testing, and increasing investments in research and clinical trials drive the growth of this region. Changing lifestyles coupled with the presence of established market players in the region have increased the demand for non-invasive prenatal testing in the region.

Competitive Landscape

The leading players in the non-invasive prenatal testing market include Agilent Technologies, Inc., Laboratory Corporation of America Holdings, Illumina, Inc., F. Hoffman-La Roche Ltd., Yourgene Health, Perkinelmer, Inc., GE Healthcare, Quest Diagnostics, Thermo Fisher Scientific, Inc., Sequenom, Qiagen N.V., Koninklijke Philips N.V., Natera, Inc., Beijing Genomics Institute, and Pacific Biosciences of California, Inc.

The aforementioned market players are expanding their presence across various geographies and entering new markets in developing regions to expand their customer base and strengthen their presence in the market. The companies are also introducing new innovative products in the market to cater to the growing consumer demands.